therapeutic drug monitoring (TDM) Flashcards

1
Q

what is therapeutic drug monitoring (TDM)?

A

the clinical practice of measuring drug concentrations (‘levels’) to optimize medication therapy for an individual patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

the process of TDM is predicted on what assumption?

A

that there is a definable relationship between dose and concentration, and between concentration and therapeutic/toxic effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

drugs that are good candidates for TDM

A

-drugs with a narrow therapeutic range/index (concentration associated with therapeutic effect overlap considerably with the concentration associated with toxic effects, such that the zone for therapeutic benefit without toxicity is very narrow)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TDM is employed for…

A
  • medications having a narrow therapeutic range/index
  • medications with a concentration-dependent efficacy/safety profile
  • medications with marked PK and/or PD variability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

medications routinely monitored through TDM

A
  • anti-seizure medications
  • cardiac medications
  • antibiotics
  • immunosuppressants
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is therapeutic (reference) range?

A
  • range of drug concentrations within which the probability of:
  • the desired clinical response is relatively high and
  • the probability of toxicity is relatively low
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

specific range for a given drug varies based on…

A
  • indication (type/site of infection and/or infecting organism/MIC with antibiotic treatment)
  • treatment stage (e.g. time post-transplant with immunosuppressant treatment)
  • dosing method (e.g. traditional vs extended-interval vs continuous infusion dosing strategies)
  • concurrent treatment (e.g. drugs with additive toxicity)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

amino glycoside treatment

A
  • peak and trough with traditional dosing

- and random level(s) with extended-interval dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

vancomycin treatment

A

trough only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

phenobarbital

A
  • post-loading dose level
  • ~2-3 hours post-dose to confirm a therapeutic concentration plus follow-up levels (trough typical, but sampling time is not important because the long half-life minimizes peak-to-trough level fluctuation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

when should levels be ordered for a medication indicating TDM?

A
  • treatment initiation
  • dose adjustment
  • change in concomitant medications having drug-drug interaction
  • change in clinical status (e.g. renal/liver impairment)
  • inadequate response (to confirm therapeutic level)
  • signs/symptoms toxicity (to rule out toxic level)
  • routine monitoring (e.g. in the outpatient setting)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how frequently should levels be ordered for a medication indicating TDM once therapeutic levels are achieved = aminoglycoside treatment

A
  • every 3-7 days

- sooner in hemodynamically unstable patients, if clinical status changes, or if signs/symptoms toxicity observed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

for vancomycin treatment

A
  • every ~7 days, if indicated

- sooner in hemodynamically unstable patients, if clinical status changes, or if signs/symptoms toxicity observed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

for phenobarbital

A
  • following establishment of the maintenance dose per post-loading dose level
  • a follow-up level may be collected 3-4 days later (before attainment of steady-state)
  • and then 3-4 weeks later (after attainment of steady-state)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

effect of renal dysfunction on renally cleared drugs?

A

-renal dysfunction will extend the t1/2 of renally cleared drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

to appropriately interpret a drug level, you will need to collect/assess the…

A
  • medication name and formulation (i.e. immediate-release vs extended-delayed-release)
  • number of medication doses (at the current dose) that were administered prior to collection of the level (i.e. steady-state achieved?)
  • medication administration time (i.e. timing of the dose prior to the collected level -> # hours post-dose?)
  • sampling time (i.e. the time at which the level was collected - is it true peak/trough level, or was it collected early/late? was the level collected during the ‘distribution phase’?)
  • historical levels (if available), and
  • compliance/adherence (if indicated)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

steady-state

A
  • at steady-state, the rate of drug entering the body = the rate of elimination
  • we typically want to know the drug concentration at steady-state
  • with respect to TDM, a drug that has attained steady-state is at its highest concentration, and when given at the same dose at a fixed interval, the concentration vs time profiles are constant from dose to dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

peak

A
  • steady-state maximum concentration

- typically measured 1/2 to 1 hour post-infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

trough

A
  • steady-state minimum concentration
  • typically measured just prior to dose
  • true tough occurs at the end of the interval (e.g. true trough is 8 hours post-dose with a q8h dosing schedule)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

if the concentration is deemed to be subtherapeutic…

A

-increase the dose or shorten the dosing interval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

if the concentration is deemed to be supratherapeutic/toxic…

A

-decrease the dose or extend the dosing interval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

TDM steps for the pharmacist…

A
  1. choose the target concentration specific for a given patient and his/her medical condition
  2. initiate treatment regimen to attain the pre-defined target concentration using population PK parameters while accounting for an individual patient’s clinical condition and baseline characteristics including but not limited to age, weight, organ function [e.g. renal dysfunction], concomitant drug therapy, and/or historical levels
  3. analyze the collected drug concentrations
  4. evaluate response in light of the resulting drug concentrations
  5. adjust the regimen as indicated using PK parameters specific to a given patient based on the drug concentrations and/or response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

steps to individualize drug therapy

A
  • perform drug-drug interaction check for all concomitant medications
  • many other steps
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

drugs that require TDM

A
  • narrow therapeutic index
  • variable pharmacokinetics: inter and intra patient variability
  • known concentration-effect relationship (efficacy and/or toxicity)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

therapeutic window vs therapeutic index

A

not the same

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

indications for TDM

A
  • pharmacokinetic dose individualization
  • monitor compliance
  • monitor for drug interactions
  • ensure efficacy/prevent toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

common drugs that require TDM: vancomycin

A
  • trough = 10-20 mcg/ml
  • AUC = 400-600 mg h/l
  • anti-bacterial
28
Q

common drugs that require TDM: gentamicin/tobramycin

A
  • peak = 6-8 mcg/ml
  • trough = 1-2 mcg/ml
  • anti-bacterial
29
Q

common drugs that require TDM: phenytoin

A
  • random = 10-20 mcg/ml

- anti-seizure

30
Q

common drugs that require TDM: warfarin

A
  • INR (international normalized ratio) = 2-3

- anti-coagulant

31
Q

pharmacokinetics

A
  • what the body does to the drug; how the drug moves throughout the body
  • ADME
32
Q

absorption

A

-disintegration, dissolution, passive/active diffusion through enterocytes of GI tract (bioavailability; first pass metabolism)

33
Q

distribution

A

binding of drug to proteins and tissues, distribution of drug throughout body

34
Q

metabolism

A

enzymatic alteration of drug molecule primarily in liver, increases ability of molecule to be eliminated

35
Q

elimination

A

removal of drug from systemic circulation primarily in kidney

36
Q

pharmacodynamics

A
  • what the drug does to the body

- receptor binding = affinity of drug for receptor

37
Q

clearance (CL)

A
  • volume of plasma that is cleared of drug per unit time
  • specific to each drug; units typically L/hr
  • may approximate creatinine CL if drug undergoes majority renal CL
38
Q

apparent volume of distribution (Vd)

A
  • pharmacokinetic rate constant - NOT A PHYSIOLOGIC TERM
  • specific to each drug; units typically L
  • may be represented as a fraction of weight
39
Q

elimination rate constant (ke)

A

ke = CL/Vd

40
Q

AUC

A
  • area under the curve

- overall drug exposure

41
Q

t1/2 (half-life)

A

-time at which drug has lost half its maximum concentration

42
Q

steady state

A
  • 4-5 half lives to achieve steady state
  • amount of drug into system = amount of drug out of system
  • peak and trough concentrations are consistent for each dose
43
Q

steady state: ideal vs reality

A
  • ideally, TDM should be performed at steady state for all drugs
  • in reality, there are many indications for TDM before achieving steady state -> ensure effective concentrations achieved to combat life-threatening infections, prevent accumulation in patients with severely reduced CL (renal or hepatic failure)
44
Q

affect of kidney dysfunction on pharmacokinetics

A
  • increase volume of distribution

- decrease kidney elimination

45
Q

affect of kidney dysfunction on pharmacodynamics

A
  • increased permeability of the blood brain barrier -> increased CNS effects
  • decreased platelet aggregation -> increased bleeding risk
46
Q

assessment of kidney function

A
  • Cockcroft-Gault estimation of CrCl
  • calculate CrCl and Ideal Body Weight (IBW) in kg
  • creatinine is a product of muscle (protein) catabolism, therefore select the body weight that most closely resembles muscle mass
47
Q

creatinine clearance (CrCl)

A

[140 - age (years) x ideal body weight (kg) / [72 x SCr (mg/dl)]
-multiple by 0.85 if female

48
Q

ideal body weight (IBW) in kg for females

A

IBW = 45.5 + (2.3 x height > 5’ in inches)

49
Q

ideal body weight (IBW) in kg for males

A

IBW = 50 + (2.3 x height > 5’ in inches)

50
Q

affect of hepatic dysfunction on pharmacokinetics

A

-decrease hepatic metabolism

51
Q

affect of hepatic dysfunction on pharmacodynamics

A
  • altered effect of certain drugs due to altered sensitivity
  • increase permeability in the BBB, increases in GABA (inhibitory neurotransmitter)
  • less albumin production in the liver -> decrease protein binding -> increase free drug available to act
52
Q

liver function assessments: Child-Pugh Score

A

Class A, Class B, Class C

-least to most severe

53
Q

class A

A

5-6 points

54
Q

class B

A

7-9 points

55
Q

class C

A

10-15 points

56
Q

vancomycin clinical pharmacokinetics

A

-initial dose = 15-20 mg/kg

57
Q

ke formula

A

ke = CL/Vd

58
Q

t1/2 formula

A

t1/2 = ln2/ke = 0.693/ke

59
Q

phenytoin TDM

A

interpretation of phenytoin concentration data is obscured in renal dysfunction due to alterations in protein binding, volume of distribution, and free drug available

60
Q

renal dysfunction patient taking phenytoin

A
  • draw FREE drug concentration whenever possible

- it has an effect on volume distribution

61
Q

warfarin principles

A
  • vitamin K antagonist
  • anti-coagulant
  • narrow therapeutic index
  • numerous drug and food interactions
62
Q

warfarin = INR too low

A

blood clots more likely

63
Q

warfarin = target INR

A
  • usually 2-3

- balance of benefits and risks

64
Q

warfarin = INR too high

A

bleeding side effects more likely

65
Q

warfarin clinical pharmacokinetics

A
  • onset of effect is 2-3 days
  • duration of effect is 2-5 days
  • half life of factor II (thrombin) is 72 hours
  • age, weight, renal function, hepatic function, genetics, concomitant medications, diet all affect dosing